Found 5 articles for: "IGA"
Ethical Dilemma: Who Benefits From Calling an Atypical Junctional Melanocytic Proliferation a Melanoma In Situ?
November 2025 | Volume 24 | Issue 11 | Features | e63 | Copyright © November 2025
Refractory Pruritus Secondary to Linear IgA Bullous Dermatosis Treated Successfully With Nemolizumab: A Case Report
October 2025 | Volume 24 | Issue 10 | Case Reports | 1041 | Copyright © October 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses
February 2025 | Volume 24 | Issue 2 | Original Article | 196 | Copyright © February 2025
Background: The pivotal Phase 3 VOYAGE 1 and VOYAGE 2 studies established the robust efficacy and safety of guselkumab for up to 5 years in patients with moderate-to-severe psori...
Read MoreDo Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry
April 2023 | Volume 22 | Issue 4 | Original Article | 344 | Copyright © April 2023
Background: Research examining associations between the clinician-reported validated Investigator Global Assessment for AD (vIGA-AD) and patient-reported disease burden is sparse...
Read MoreA Case of Successful Management of Adult-Onset Linear IgA Bullous Disease With Sulfasalazine During the COVID-19 Pandemic
December 2022 | Volume 21 | Issue 12 | Case Reports | 1355 | Copyright © December 2022
Linear IgA bullous disease (LABD) is a rare, acquired, autoimmune, pruritic, and blistering skin condition. Dapsone is a first line treatment option, however, there are limited options if this fails, ...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.